Oppenheimer Reiterates Outperform on Praxis Precision Medicine, Raises Price Target to $143
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating for Praxis Precision Medicine (NASDAQ:PRAX) and increased the price target from $134 to $143.
September 04, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating for Praxis Precision Medicine and increased the price target from $134 to $143, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and an increased price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100